TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04138862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Product Labelling and Sensory modifications
Description: the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Product Labelling and Sensory modifications
Description: the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Product Labelling and Sensory modifications
Description: the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Product Labelling and Sensory modifications
Description: the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
Study: NCT04373187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: one injection of 2mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: one injection of 2mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: two injections of 1.2mL
Study: NCT00704756

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered based on body weight 800-1200 mg/day (\<65 kg : 800 mg, 65 - 85 kg : 1000 mg, \>85 kg : 1200 mg) orally for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
Study: NCT03971747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP Specific T Cell Receptor T Cells
Description: Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
Study: NCT04178395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial direct stimulation
Description: tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bihemispheric transcranial direct stimulation
Description: tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA).
Study: NCT02020018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Incision Management System
Description: negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sterile dry wound dressing
Description: regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
Study: NCT03492632

Intervention type: OTHER
Intervention: Hormone panel
Description: Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.

Intervention type: OTHER
Intervention: Hormone panel
Description: Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
Study: NCT02265731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitadine
Description: 75 mg/m2 by IV infusion or subcutaneous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Step-up doses of venetoclax to the designated cohort dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Step-up doses of venetoclax to the designated cohort dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Step-up doses of venetoclax to the designated cohort dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Step-up doses of venetoclax to the designated cohort dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab / IDEC-C2B8
Description: 375 mg/m2 on Week 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab / IDEC-C2B8
Description: 500 mg/m2 Week 10 Day 1 and thereafter
Study: NCT03696758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: Subjects will undergo positron magnetic resonance imaging to detect images of the heart

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: Subjects will undergo positron magnetic resonance imaging to detect images of the heart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
Study: NCT02709343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone-marrow derived MSCs
Description: Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product visually very similar to mesenchymal stromal cells
Study: NCT02980380

Intervention type: OTHER
Intervention: Non-invasive brain computer interface
Description: The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication.
Study: NCT02605434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accordion Pill™ Carbidopa/Levodopa
Description: AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet®
Description: Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo -AP-CD/LD
Description: Placebo for AP-CD/LD capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo- Sinemet
Description: Placebo for Sinemet tables
Study: NCT01236989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anatomical liver resection
Description: anatomical liver resection by means of IOUS-finger compression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-anatomical liver resection
Description: non-anatomical liver resection
Study: NCT00300456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks
Study: NCT03696758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
Study: NCT04346134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-PNL
Description: Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWL
Description: Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
Study: NCT00490503

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: 3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy (MRS)
Description: 3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
Study: NCT03080376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based intervention with support
Description: Web-based combined aerobics and muscular strength exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based intervention without support
Description: Web-based combined aerobics and muscular strength exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional intervention
Description: 3 months of Printed-based combined aerobics and muscular strength exercise intervention.
Study: NCT00843830

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tumoral irradiation
Description: On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Description: Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
Study: NCT03180528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remetinostat
Description: Applied topically under bandage occlusion
Study: NCT01854255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin and cisplatin
Description: doxorubicin and cisplatin as intraperitoneal chemotherapy
Study: NCT00798681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RTU TPN with olive oil as the primary lipid source
Description: RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CNF Parenteral nutrition
Description: CNF parenteral nutrition made with olive oil as the primary source of lipids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CNF parenteral nutrition
Description: 3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
Study: NCT00939627

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00300456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: daily, 12 weeks, see Arm Description for dosage information
Study: NCT02160431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for pediatric OCD
Description: Participants complete standard CBT for OCD as delivered in the POTS study .
Study: NCT03261804

Intervention type: BEHAVIORAL
Intervention: relation between vaginal douching and vaginal infection
Description: personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.

Intervention type: BEHAVIORAL
Intervention: relation between vaginal douching and vaginal infection
Description: personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
Study: NCT03769155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Undergo therapeutic conventional surgery
Study: NCT02105129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
Study: NCT02681380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relation learning
Description: Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No session will be planned for the participants.
Study: NCT02105129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT03068000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Judo Training
Description: Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
Study: NCT04386564

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA in urine test
Description: Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
Study: NCT03068000

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ball Games
Description: The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
Study: NCT01557049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Reeducation Group
Description: They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
Study: NCT04157543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture with electricity

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: acupuncture with electricity
Study: NCT02973490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanal Tube Drainage
Description: Using transanal tube drainage after colorectal ESD
Study: NCT01157923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD Logic Pump Advisor
Description: Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
Study: NCT01228643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic enzimes
Description: - Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Creon ®
Description: - Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
Study: NCT02476201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPP ON
Description: Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
Study: NCT04386564

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA in urine test
Description: Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed

Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA in urine test
Description: Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
Study: NCT02585843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg
Description: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 25mg
Description: 25mg/day of spironolactone
Study: NCT03490708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Subjects will be treated with tranilast
Study: NCT04121923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Ring Pulse Oximeter
Description: Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
Study: NCT00915122

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose Escalated IMRT
Description: Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
Study: NCT03191188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Description: Thyroid hormone supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT00978978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol VS. midazolam and fentanyl, endoscopies, liver diseases
Description: 1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol VS. midazolam and fentanyl, endoscopies, liver diseases
Description: 1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists